Q2-2016 Pharmacy Services Update



M&A Overview

Although the volume of transactions in the second quarter of 2016 was relatively low, the size of the companies acquired and their prominence in the specialty pharmacy sector is particularly noteworthy. Strategic buyers drove the M&A market, with McKesson, Diplomat, and Premier all being active. Their target companies were all sizeable, with annual revenues in excess of \$200 million each. The main themes in the deals were expanding geographic reach and/or disease state expertise. We expect private equity to re-enter the M&A landscape in the coming quarters and strategic buyers to continue to seek acquisitions that better position them with manufacturers and payors, as well as increase access to limited distribution drugs. Additionally, it is important to note that Walgreens Boots is still seeking approval for its acquisition of Rite Aid, and management expects the deal to close in the second half of 2016.

Noteworthy Transactions

Public Company Valuations

Data from Capital IQ as of June 30, 2016			Valuation Statistics	
Company	Ticker	Enterprise Value (EV) – in millions	EV/ LTM Rev.	EV/ LTM EBITDA
CVS Health	CVS	\$128,437.88	0.80x	10.63x
Express Scripts	ESRX	\$62,794.78	0.62x	9.24x
PharMerica Corp.	РМС	\$1,110.01	0.54x	8.50x
Rite Aid Corp.	RAD	\$14,683.92	0.45x	11.13x
Walgreens Boots	WBA	\$100,770.06	0.86x	12.55x

Month	Acquirer	Target Company	Details	
June 2016	Premier	Lincare's Acro Pharmaceutical DivisionPremier, a leading healthcare improvement company, has agreed to put the national specialty pharmacy operations of Lincare Holdings for million. The acquisition includes Acro Pharmaceutical Service Community Pharmacy Services. The acquired operations generated million in revenue in 2015 and will serve to expand and diversify Pre- 		
June 2016	Diplomat Pharmacy	TNH Advanced Specialty Pharmacy	I Diplomat's speciality services with the acquisition of TNH. This partnership I	
April 2016	McKesson	Biologics & Vantage Oncology	McKesson has completed its previously announced acquisition of Biologics an oncology pharmacy services company. Biologics became part o McKesson's Specialty Health business, expanding McKesson's practice management solutions that allow oncologists to enhance patient care McKesson also acquired Vantage Oncology, a leading national provider o radiation oncology, medical oncology, and integrated cancer care. The two acquisitions totaled \$1.2 billion and will significantly bolster McKesson's oncology offerings for manufacturers, payers, providers, and patients.	